Deep-vein thrombosis prophylaxis in orthopedic surgery: Hip surgery

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue SUPPL. 3, 1999, Pages 79-82

  Lassen, Michael R ^a,b   Backs, Søren ^a,b   Borris, Lars C ^a,b,c   Kaltoft Srenson, Mette ^b,c   Coff Ganes, Helle ^b,c   Jeppesen, E N A ^a,b,c  

^a Department of Orthopaedic Surgery and Trauma ^*  (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Deep vein thrombosis; Hip replacement surgery; Low molecular weight heparin; Prevention

Indexed keywords

ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; REVIPARIN; TINZAPARIN;

BIOEQUIVALENCE; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HIP SURGERY; HUMAN; META ANALYSIS; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR;

ARTHROPLASTY, REPLACEMENT, HIP; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; META-ANALYSIS; ORTHOPEDICS; VENOUS THROMBOSIS;

EID: 0032753660     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BrMed J 1992:305:567-574
2. Clagett GP, Anderson FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995;108(Suppl): 312-334
3. Jorgensen LN, Wille-Jorgensen P, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Br J Surg 1993:80:689-704
4. Nurmohamed MT, Rosendaal FR, Biiller HR, et al. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis. Lancet 1992;340:152-156
5. Palmer AJ, Koppenhagen K, Kirchof B, Weber U, Bergemann R. Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thromboembolism prophy-laxis in orthopaedic surgery: A meta-analysis of randomized clinical trials. Haemostasis 1997;27:75-84
6. Leizorovicz A, Haugh MC, Chapuis F-R, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992:305:913-920
7. Bergqvist D. Low molecular weight heparins. J Intern Med 1996:240:63-72
8. Fareed J, Hoppensteadt D, Jeske W, Clarizio R, Walenga JM. Low molecular weight heparins: Are they different? Can J Cardiol 1998;14(supplE):28E-34E
9. Kalodiki E, Nicolaides AN, Al-Kutoubi A, Cunningham DA, Mandalia S. How "gold" is the standard? Interobservers' variation on venograms. Int Angiol 1998:17:83-88
10. Couson F, Bounameaux C, Didier D, et al. Influence of variability of interpretation of contrast venography for screening of postoperative deep venous thrombosis on the results of a thromboprophylactic study. Thromb Haemost 1993:70:573-575
11. Wille-Jorgensen P, Borris LC, Lassen MR, et al. Potential influence of observer variation in thromboprophylactic trials. Haemostasis 1992;22:211-215
12. Clarke MT, Green JS, Harper WM, Gregg PJ. Cement as a risk factor for deep-vein thrombosis. Comparison of cemented TKR, uncemented TKR, and cemented THR. J Bone Joint Surg Br 1998:80:611-613
13. Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: A randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988;60:407-4110
14. Borris LC, Sorensen JV, Lassen MR, et al. Components of coagulation and fibrinolysis during thrombosis prophylaxis with a low molecular weight heparin (enoxaparin) versus Dextran 70 in hip arthroplasty. Thromb Res 1991:63:21-28
15. Kalodiki EP, Hoppensteadt DA, Nicolaides AN, et al. Deep-vein thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomized controlled trial. Int Angiol 1996;15:162-168
16. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997:337:1329-1335
17. Planes A, Vochelle N, Fagola M, Bellaud M. Comparison of two low molecular weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Re-viparin Study Group. Blood Coag Fibrinolysis 1998;9: 499-505
18. Warwick D, Harrison J, Glew D, et al. Comparison of the use of a foot pump with the use of low molecular weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial. J Bone Joint Surg Am 1998;80:1158-1166
19. Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomized comparison of enoxaparin versus placebo. Lancet 1996;348:224-228
20. Bergqvist D, Benoni G, Bjorgell O, et al. Low molecular weight heparin (enoxaparin) as prophylaxis against thromboembolism after total hip replacement. N Engl J Med 1996; 335:696-700
21. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery-results of a doubleblind, prospective, randomized, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost 1997;77:26-31
22. Lassen MR, Borris LC, Anderson BS, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip anhroplasty-the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res 1998; 89:81-87
23. Planes A, Samama MM, Lensing AW, et al. Prevention of deep vein thrombosis after hip replacement-comparison between two low molecular heparins, tinzaparin, and enoxaparin. Thromb Haemost 1999;81:22-25
24. Noble S, Peters DH, Goa KL. Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs 1995;49:388-410
25. Hawkins DW, Langley PC, Krueger KP. Pharmacoeconomic model of enoxaparin versus heparin for prevention of deepvein thrombosis after total hip replacement. Am J Health Syst Pharml997;54:1185-1190
26. O'Brien BJ, Anderson DR, Goeree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. Can Med Assoc J 1994; 150: 1083-1090
27. Drummond M, Aristides M, Davies L, Forbes C. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Br J Surg 1994;81:1742-1746